These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36548711)

  • 1. How Botulinum Neurotoxin Light Chain A1 Maintains Stable Association with the Intracellular Neuronal Plasma Membrane.
    Gardner AP; Barbieri JT; Pellett S
    Toxins (Basel); 2022 Nov; 14(12):. PubMed ID: 36548711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of Two Steps in Botulinum Neurotoxin Serotype A1 Light Chain Localization to the Intracellular Plasma Membrane.
    Gardner A; Tepp WH; Bradshaw M; Barbieri JT; Pellett S
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
    Pellett S; Bradshaw M; Tepp WH; Pier CL; Whitemarsh RCM; Chen C; Barbieri JT; Johnson EA
    mBio; 2018 Mar; 9(2):. PubMed ID: 29588398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.
    Chen S; Barbieri JT
    J Biol Chem; 2011 Apr; 286(17):15067-72. PubMed ID: 21378164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
    Kohda T; Tsukamoto K; Torii Y; Kozaki S; Mukamoto M
    Microbiol Immunol; 2020 Jul; 64(7):502-511. PubMed ID: 32301520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalytic properties of botulinum neurotoxin subtypes A3 and A4.
    Henkel JS; Jacobson M; Tepp W; Pier C; Johnson EA; Barbieri JT
    Biochemistry; 2009 Mar; 48(11):2522-8. PubMed ID: 19256469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3.
    Leka O; Wu Y; Li X; Kammerer RA
    J Biol Chem; 2021; 296():100684. PubMed ID: 33891946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
    Kull S; Schulz KM; Weisemann J; Kirchner S; Schreiber T; Bollenbach A; Dabrowski PW; Nitsche A; Kalb SR; Dorner MB; Barr JR; Rummel A; Dorner BG
    PLoS One; 2015; 10(2):e0116381. PubMed ID: 25658638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1.
    Lam KH; Guo Z; Krez N; Matsui T; Perry K; Weisemann J; Rummel A; Bowen ME; Jin R
    Nat Commun; 2018 Dec; 9(1):5367. PubMed ID: 30560862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.
    Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR
    Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain.
    Tepp WH; Bradshaw M; Gardner AP; Kaufman RL; Barbieri JT; Pellett S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
    Davies JR; Rees J; Liu SM; Acharya KR
    J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.
    Kroken AR; Blum FC; Zuverink M; Barbieri JT
    Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of botulinum neurotoxin subtype A3 cell binding domain in complex with GD1a co-receptor ganglioside.
    Gregory KS; Liu SM; Acharya KR
    FEBS Open Bio; 2020 Mar; 10(3):298-305. PubMed ID: 31945264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.
    Gul N; Smith LA; Ahmed SA
    PLoS One; 2010 Sep; 5(9):e12872. PubMed ID: 20877571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma membrane localization signals in the light chain of botulinum neurotoxin.
    Fernández-Salas E; Steward LE; Ho H; Garay PE; Sun SW; Gilmore MA; Ordas JV; Wang J; Francis J; Aoki KR
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3208-13. PubMed ID: 14982988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.
    Band PA; Blais S; Neubert TA; Cardozo TJ; Ichtchenko K
    Protein Expr Purif; 2010 May; 71(1):62-73. PubMed ID: 20045734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").
    Pellett S; Tepp WH; Lin G; Johnson EA
    Toxicon; 2018 Jun; 147():38-46. PubMed ID: 29273248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.